In ongoing research, we are trying to identify additional TCRs targeting KRAS mutations in human pancreatic cancer patients with other KRAS mutations or HLA expression using our sequential in vitro stimulation approach. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.